Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synovial predictors of infliximab response in rheumatoid arthritis
NL-OMON28799Active, not recruiting
- Sponsor
- AMC Health
- Start
- Apr 2001
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in rheumatoid arthritis (RA), sponsored by AMC Health. Primary endpoints: Primary immunohistologic outcome and Primary clinical outcome. Started Apr 2001; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON28799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28799.